Shares of MBX Biosciences, Inc. (NYSE:MBX - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $18.94, but opened at $19.45. MBX Biosciences shares last traded at $19.85, with a volume of 20,621 shares.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on MBX shares. Jefferies Financial Group started coverage on shares of MBX Biosciences in a report on Tuesday, October 8th. They issued a "buy" rating and a $35.00 price target for the company. Guggenheim began coverage on MBX Biosciences in a research report on Tuesday, October 8th. They set a "buy" rating and a $44.00 target price for the company. JPMorgan Chase & Co. started coverage on MBX Biosciences in a report on Tuesday, October 8th. They issued an "overweight" rating and a $30.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on MBX Biosciences in a research report on Tuesday, October 8th. They issued a "buy" rating and a $40.00 price objective for the company.
Get Our Latest Research Report on MBX
MBX Biosciences Stock Up 1.1 %
The company has a 50-day simple moving average of $21.39.
MBX Biosciences (NYSE:MBX - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($2.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.72) by ($0.06). Equities analysts forecast that MBX Biosciences, Inc. will post -13.21 EPS for the current year.
Institutional Investors Weigh In On MBX Biosciences
A number of hedge funds have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in MBX Biosciences during the third quarter worth $278,000. Point72 Asset Management L.P. acquired a new stake in shares of MBX Biosciences in the 3rd quarter valued at approximately $405,000. Barclays PLC bought a new position in shares of MBX Biosciences in the third quarter valued at $426,000. Geode Capital Management LLC acquired a new position in MBX Biosciences during the third quarter worth $579,000. Finally, Point72 DIFC Ltd acquired a new position in MBX Biosciences during the third quarter worth $624,000.
MBX Biosciences Company Profile
(
Get Free Report)
MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
Recommended Stories
Before you consider MBX Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list.
While MBX Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
